Tainan
TAINAN, Taiwan, February 8, 2011 - ScinoPharm, a leading active pharmaceutical ingredient (API) and contract
research and manufacturing (CRAM) service provider to the global
pharmaceutical and biotechnology industry, will provide commercial
manufacturing service of vilazodone hydrochloride active pharmaceutical
ingredient (API) for Clinical Data, Inc.'s Viibryd(TM), a new drug entity
recently approved by the United States Food and Drug Administration.
TAINAN, Taiwan, August 31, 2010 - ScinoPharm, a leading active pharmaceutical ingredient (API) developer
and manufacturer headquartered in Taiwan, today announced an investment into
Tanvex Biologics, Inc., a United States company registered in the State of
Delaware.
TAINAN, Taiwan -
Eli Lilly & Company ("Lilly") and ScinoPharm Taiwan Ltd.
